This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

This database contains 202 studies, archived under the term: "drug effects"

Click here to filter this large number of results.

Demonstration of safety in Alzheimer’s patients for intervention with an anti-hypertensive drug Nilvadipine: results from a 6-week open label study
Background: Nilvadipine may lower rates of conversion from mild-cognitive impairment to Alzheimer’s disease (AD), in hypertensive patients. However, it remains to be determined whether treatment with nilvadipine is safe in AD patients, given the higher incidence of orthostatic hypotension (OH) in this population, who may be more likely to suffer from symptoms associated with the […]

Long-term effects of galantamine on cognitive function in Alzheimer’s disease: a large-scale international retrospective study
In Alzheimer’s disease (AD), it is important to consider long-term effects, not only in patients receiving treatment, but also in subjects in whom therapy has been discontinued. The present analysis evaluates the long-term effects of galantamine on cognitive function in AD in terms of Mini-Mental State Examination (MMSE) scores for up to 7 years, using […]

The effects of oxytocin on social cognition and behaviour in frontotemporal dementia
Patients with behavioural variant frontotemporal dementia demonstrate abnormalities in behaviour and social cognition, including deficits in emotion recognition. Recent studies suggest that the neuropeptide oxytocin is an important mediator of social behaviour, enhancing prosocial behaviours and some aspects of emotion recognition across species. The objective of this study was to assess the effects of a […]

Evaluation of the effects of galantamine on cardiac function in elderly patients with Alzheimer’s disease
Background: Galantamine, a cholinesterase inhibitor, is used as a first-line drug in the treatment of Alzheimer’s disease (AD). However, it may have vagotonic effects, which may cause bradycardia and/or heart block in patients with or without a history of cardiac disease.; Objective: The purpose of this study was to evaluate the effects of galantamine on […]

Omega-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer’s disease: the omega-3 Alzheimer’s disease study
Objectives: To study the effects of omega (Omega)-3 fatty acid (FA) supplements on weight and appetite in patients with mild to moderate Alzheimer’s disease (AD) in relation to inflammatory biomarkers and apolipoprotein E epsilon4 (APOEepsilon4).; Design: Randomized, double-blind, placebo-controlled trial.; Setting: Specialist memory clinics in the Stockholm catchment area.; Participants: Two hundred four patients (aged […]

Long-term statin therapy is associated with better episodic memory in aged familial hypercholesterolemia patients in comparison with population controls
The cognitive status of aged familial hypercholesterolemia (FH) patients treated with long-term statin therapy was compared with that of population controls. A comprehensive cohort of 43 elderly (age > or = 65 years) patients all with the same FH North Karelia mutation living in North Karelia (eastern Finland) was identified, 37 of whom (aged 65 […]

Combating depression in Huntington’s disease: effective antidepressive treatment with venlafaxine XR
Patients with Huntington’s disease (HD) often suffer from psychiatric symptoms including affective disorder, psychosis, irritability, and apathy, which may be present in all stages of the disease. However–despite the obvious likelihood that these symptoms may be reduced by antidepressive treatments–to date, the effectiveness of such treatments in HD has only ever been examined in case […]

A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer’s disease
Background: Agitation and aggression in Alzheimer’s disease (AD) are amongst the most serious of neuropsychiatric symptoms, and contribute to poor outcomes and worse quality of life. Previous studies have suggested a benefit for memantine on agitation and aggression, but none have examined its efficacy in community-dwelling patients with significant agitation and aggression at baseline, utilizing […]

Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial
Objectives: To compare the effects of three antihypertensive medications on cerebral hemodynamic and cognitive function in hypertensive individuals with executive dysfunction.; Design: Double-blind randomized clinical trial.; Setting: Community.; Participants: Fifty-three individuals aged 60 and older with hypertension and executive dysfunction.; Intervention: Lisinopril, candesartan, or hydrochlorothiazide for 1 year.; Measurements: Cerebral blood flow velocity (BFV; transcranial […]

A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer’s disease
Introduction: Histaminergic H3 receptors may play a role in modulating cholinergic and monoaminergic neurotransmission. This Phase II study evaluated the efficacy and safety of GSK239512, a highly potent, brain penetrant H3 receptor antagonist as monotherapy treatment for subjects with mild-to-moderate probable Alzheimer’s disease (AD).; Methods: In this 16-week, double-blind, randomized, parallel group study, 196 currently […]

Try searching our database by another keyword...

To make a new query of the database, please enter your search terms below:

�

Contact Us